Voices
Masahiro Torasawa
Masahiro Torasawa/X

Masahiro Torasawa: How Can Skin Toxicity of Amivantamab and Lazertinib be Reduced?

Masahiro Torasawa, Medical Oncologist at Juntendo University, shared a post on X:

“How to Reduce Skin Toxicity of Amivantamab + Lazertinib? – COCOON Trial (Ph2)

Key Results

  • Significantly reduced Gr ≥2 dermatologic AEs within 12 weeks (42% vs 75%, p<0.0001).
  • Less impact of skin symptoms on QoL.
  • Delayed time to onset of severe skin AEs (median 1.0 mo → 3.5 mo).
  • Limited effect on paronychia  (21% vs 23%; p=0.76)

Discussion

  • A simple, widely available prophylactic regimen greatly improves tolerability in clinical practice.
  • Essential supportive care to maximize the efficacy benefits seen in the MARIPOSA trial.
  • New strategies are needed to manage paronychia.
  • Prophylactic anticoagulation for the first 4 months is also effective for VTE risk.

Masahiro Torasawa: How Can Skin Toxicity of Amivantamab and Lazertinib be Reduced?

Grade 2 or higher skin or nail adverse events were significantly reduced with the regimen as described.”

Masahiro Torasawa: How Can Skin Toxicity of Amivantamab and Lazertinib be Reduced?

Title: Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial

Authors: Byoung Chul Cho, Weimin Li, Alexander I. Spira, Maxwell Sauder, Jill Feldman, Farastuk Bozorgmehr, Milena Mak, Janellen Smith, Pei Jye Voon, Baogang Liu, Panwen Tian, Jiunn-Liang Tan, Cheng-Ta Yang, Jin-Yuan Shih, Nuri Karadurmus, Juan Esteban Cundom, Glaucio Bertollo, Irfan Cicin, Jorge Nieva, Ana Laura Ortega-Granados, Pascale Tomasini, Danny Nguyen, Enriqueta Felip, Julia Schuchard, Sean P. Murphy, Bailey G. Anderson, Tonatiuh Romero, Yichuan Xia, Shubin Sheng, Joshua M. Bauml, Parthiv J. Mahadevia, Julian Kam, Mehregan Nematian-Samani, Jairo Simoes, Mark Wildgust, Nicolas Girard

Read the Full Article on Journal of Thoracic Oncology

Masahiro Torasawa: How Can Skin Toxicity of Amivantamab and Lazertinib be Reduced?

More posts featuring Masahiro Torasawa.

Alexander I. Spira Amivantamab Ana Laura Ortega-Granados Bailey G. Anderson Baogang Liu Byoung Chul Cho cancer Cheng-Ta Yang COCOON trial Danny Nguyen Enriqueta Felip Farastuk Bozorgmehr Glaucio Bertollo Irfan Cicin Jairo Simoes Janellen Smith Jill Feldman Jin-Yuan Shih Jiunn Liang Tan Jorge Nieva Joshua M. Bauml Juan Esteban Cundom Julia Schuchard Julian Kam lazertinib Mark Wildgust Masahiro Torasawa Maxwell Sauder Mehregan Nematian-Samani Milena Mak Nicolas Girard Nuri Karadurmus OncoDaily Oncology Panwen Tian Parthiv J. Mahadevia Pascale Tomasini Pei Jye Voon Sean P. Murphy Shubin Sheng Tonatiuh Romero Weimin Li Yichuan Xia